NASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $0.24 +0.01 (+2.74%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.24 +0.01 (+2.08%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$0.23▼$0.2550-Day Range$0.23▼$0.3052-Week Range$0.20▼$5.14Volume718,217 shsAverage Volume426,941 shsMarket Capitalization$10.65 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingReduce Company Overview Vistagen Therapeutics, Inc. (NASDAQ: VTGN), formerly known as VistaGen Therapeutics, is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The company’s research centers on neuroactive nasal spray medicines designed to act rapidly and potentially avoid some of the systemic side effects associated with conventional treatments. Vistagen’s lead product candidate is fasedienol, also known as PH94B, an investigational nasal spray being developed for anxiety-related disorders, including social anxiety disorder. The company is also advancing PH10, an intranasal neuroactive drug candidate being studied for depressive disorders, and PH80, a nasal spray candidate investigated for conditions such as migraine. These products remain investigational and have not been approved for commercial use. Vistagen’s product candidates originated from research involving pherines, synthetic neuroactive compounds intended to influence neural pathways through the nasal cavity. The company is headquartered in South San Francisco, California, and its development activities are primarily focused on the U.S. market. Vistagen is led by President and Chief Executive Officer Shawn K. Singh.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 693rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingVistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialVistaGen Therapeutics has a consensus price target of $0.95, representing about 295.8% upside from its current price of $0.24.Amount of Analyst CoverageVistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.94% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 2.79, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently increased by 8.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for VTGN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.93% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesVistaGen Stockholders Reaffirm Board, Governance and OversightSeptember 11, 2026 | tipranks.comVistagen to Present at Psych Congress 2026September 10, 2026 | globenewswire.comWhat Elon Musk did in June 2024In June 2024, Elon Musk faced a problem every AI company was about to hit — how to power a massive AI computer fast. Just 122 days later, it was running. Meta, OpenAI, and Microsoft followed with multi-decade contracts. Blackstone put in 5.34 billion dollars, and a related income vehicle has paid an average of 7 billion dollars every 90 days.September 20 at 1:00 AM | Behind the Markets (Ad)Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAugust 14, 2026 | globenewswire.comVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAugust 6, 2026 | globenewswire.comSRX Global (NYSE American: SRXH) Acquires Stake in Vistagen TherapeuticsAugust 4, 2026 | markets.businessinsider.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comStifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)July 18, 2026 | theglobeandmail.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $0.6619 on January 1st, 2026. Since then, VTGN stock has decreased by 63.7% and is now trading at $0.24. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its earnings results on Friday, August, 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 152.59% and a negative net margin of 2,702.64%. When did VistaGen Therapeutics' stock split? Shares of VistaGen Therapeutics reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are VistaGen Therapeutics' major shareholders? Top institutional investors of VistaGen Therapeutics include ADAR1 Capital Management LLC (0.79%), BlackRock Inc. (0.78%), BlackRock Inc. (0.58%) and Man Group plc (0.25%). View institutional ownership trends. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2026Today9/20/2026Next Earnings (Estimated)11/12/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VTGN's financial health is in the Red zone, according to TradeSmith. VTGN has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees41Year Founded1998Price Target and Rating Average Price Target for VistaGen Therapeutics$0.95 High Price Target$1.00 Low Price Target$0.90 Potential Upside/Downside+295.8%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net Margins-2,702.64% Pretax Margin-2,702.36% Return on Equity-152.59% Return on Assets-117.45% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$1.27 million Price / Sales8.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.27Miscellaneous Outstanding Shares44,380,000Free Float43,077,000Market Cap$10.65 million OptionableOptionable Beta0.39 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VTGN) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
